These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Ondansetron; further progress in the prevention of nausea and vomiting induced by anti-cancer chemotherapy. Sagar SM; Bayliss MA; Chong SL; Retsas S Clin Oncol (R Coll Radiol); 1991 May; 3(3):183. PubMed ID: 1829958 [No Abstract] [Full Text] [Related]
3. [Efficacy of ondansetron in acute and delayed cisplatin-induced nausea and vomiting]. Depierre A Bull Cancer; 1996 Feb; 83(2):147-53. PubMed ID: 8652909 [TBL] [Abstract][Full Text] [Related]
4. Ondansetron to prevent vomiting after cancer chemotherapy. Med Lett Drugs Ther; 1991 Jun; 33(847):63-4. PubMed ID: 1828531 [No Abstract] [Full Text] [Related]
5. Anti-emetic control with ondansetron in the chemotherapy of breast cancer: a review. Marschner N Eur J Cancer; 1991; 27 Suppl 1():S15-7; discussion S22. PubMed ID: 1831629 [TBL] [Abstract][Full Text] [Related]
6. A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. Hainsworth J; Harvey W; Pendergrass K; Kasimis B; Oblon D; Monaghan G; Gandara D; Hesketh P; Khojasteh A; Harker G J Clin Oncol; 1991 May; 9(5):721-8. PubMed ID: 1826739 [TBL] [Abstract][Full Text] [Related]
7. Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Hawthorn J; Cunningham D Br J Cancer; 1990 Jan; 61(1):56-60. PubMed ID: 2137008 [TBL] [Abstract][Full Text] [Related]
8. A randomised, double-blind, parallel-group study to compare the efficacy and safety of ondansetron (GR38032F) plus dexamethasone with metoclopramide plus dexamethasone in the prophylaxis of nausea and emesis induced by carboplatin chemotherapy. du Bois A; McKenna CJ; Andersson H; Lahousen M; Kitchener H; Pinter T; Capstick V; Wilkinson JR Oncology; 1997; 54(1):7-14. PubMed ID: 8978585 [TBL] [Abstract][Full Text] [Related]
9. Antagonism of serotonin S3 receptors with ondansetron prevents nausea and emesis induced by cyclophosphamide-containing chemotherapy regimens. Cubeddu LX; Hoffman IS; Fuenmayor NT; Finn AL J Clin Oncol; 1990 Oct; 8(10):1721-7. PubMed ID: 2145400 [TBL] [Abstract][Full Text] [Related]
10. Infusion of palonosetron plus dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Hajdenberg J; Grote T; Yee L; Arevalo-Araujo R; Latimer LA J Support Oncol; 2006 Oct; 4(9):467-71. PubMed ID: 17080735 [TBL] [Abstract][Full Text] [Related]
11. Ondansetron vs dexamethasone for chemotherapy-induced emesis. Lancet; 1991 Aug; 338(8765):478-9. PubMed ID: 1714531 [No Abstract] [Full Text] [Related]
12. Effects of ondansetron on chemotherapy-induced acute and delayed emesis--a pilot study. Johansson S; Steineck G; Hursti T; Fredrikson M; Fürst CJ; Peterson C Acta Oncol; 1991; 30(5):649-51. PubMed ID: 1832550 [No Abstract] [Full Text] [Related]
13. Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F). Campora E; Vidili G; Oliva C; Ardizzoni A; Rosso R Oncology; 1991; 48(5):403-5. PubMed ID: 1836058 [TBL] [Abstract][Full Text] [Related]
14. Ondansetron plus dexamethasone: an effective combination in high-dose cisplatin therapy. The Italian Oncology Group for Clinical Research. Tonato M Eur J Cancer; 1991; 27 Suppl 1():S12-4; discussion S22. PubMed ID: 1831628 [TBL] [Abstract][Full Text] [Related]
15. The role of ondansetron in paediatric patients: a review of three studies. Stevens RF Eur J Cancer; 1991; 27 Suppl 1():S20-2. PubMed ID: 1831631 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of GR38032F in the prophylaxis of ifosfamide-induced nausea and vomiting. Green JA; Watkin SW; Hammond P; Griggs J; Challoner T Cancer Chemother Pharmacol; 1989; 24(2):137-9. PubMed ID: 2525078 [TBL] [Abstract][Full Text] [Related]
17. Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis. Rosso R; Campora E; Cetto G; Fosser V; Marangolo M; Oliva C Anticancer Res; 1991; 11(2):937-9. PubMed ID: 1829602 [TBL] [Abstract][Full Text] [Related]
18. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy. Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854 [TBL] [Abstract][Full Text] [Related]
19. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. Roila F; Tonato M; Cognetti F; Cortesi E; Favalli G; Marangolo M; Amadori D; Bella MA; Gramazio V; Donati D J Clin Oncol; 1991 Apr; 9(4):675-8. PubMed ID: 1829757 [TBL] [Abstract][Full Text] [Related]
20. [Evaluation of the anti-emetic effectiveness of two drug formulations of Ondansetron in combined chemotherapy for children with malignant tumors]. Safonova SA; Gershanovich ML; Punanov IuA; Kolygin BA Vopr Onkol; 1999; 45(4):424-8. PubMed ID: 10532104 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]